Anuncio • Dec 16
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.05961 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.05961 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 662,332
Price\Range: £0.09 Anuncio • Dec 12
CRISM Therapeutics Corporation has filed a Follow-on Equity Offering in the amount of £0.1 million. CRISM Therapeutics Corporation has filed a Follow-on Equity Offering in the amount of £0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,111,111
Price\Range: £0.09 Anuncio • Dec 11
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £1 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 11,111,112
Price\Range: £0.09
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing Anuncio • Oct 14
CRISM Therapeutics Corporation Announces Positive Preclinical Data in Prostate Cancer and Prestative Doctoral Award CRISM Therapeutics Corporation announced significant preclinical findings and a new research collaboration that mark key milestones in the development of its innovative ChemoSeed platform in prostate cancer. Prostate cancer, the most prevalent cancer in men, is the second programme in CRISM's pipeline of product opportunities using the implantable ChemoSeed drug delivery platform. The Company's most advanced programme, irinotecan-ChemoSeed in glioblastoma, remains on track for the first patients to be dosed in an open label Phase 2 clinical trial in early 2026. In vitro studies conducted by CRISM Therapeutics have demonstrated that the sustained administration of docetaxel to prostate cancer cell lines is significantly more effective than the intermittent dosing schedules currently used in the standard of care. Sustained administration killed 72% of the prostate cancer cells compared with 65% with intermittent dosing. Furthermore, the concentration of docetaxel needed to inhibit 50% (IC 50) of prostate cancer cells from growing was 3.5nM for sustained administration compared with 9.8nM for intermittent dosing. The lower the IC 50, the more potent the treatment. Finally, at lower doses sustained administration of docetaxEL resulted in continued reduction of prostate cancer cells for 12 days, whereas with intermittent dosing there was less reduction in the prostate cancer cells and the cells started to regrow by day 9. These findings strongly support the hypothesis that sustained, localised delivery of chemotherapy, enabled by CRISM's proprietary ChemoSeed Drug delivery platform, could substantially enhance the efficacy of docetaxel, a generic chemotherapy drug, in the treatment of prostate cancer. Furthermore, with ChemoSeed this increase in efficacy could be achieved with lower amounts of docetaxel being given to the patient reducing the unwanted side effects typically seen with this drug. In addition, CRISM has successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over a period of at least 28 days. This major technical milestone confirms the feasibility of using ChemoSeed for prolonged, controlled delivery of docetaxel directly into prostate tumours, addressing a major limitation of current systemic chemotherapy approaches. Further strengthening its R&D capabilities, CRISM announced it has been awarded a prestigious Department for the Economy ("DfE") Collaborative Doctoral Partnership ("CDP") studentship in collaboration with Ulster University. This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in the personalised treatment of prostate cancer, including potential patient-specific dosing strategies and tumour-targeting delivery models. The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy. The partnership with Ulster University will further accelerate the progress and help bring this innovative treatment to patients faster. Anuncio • Sep 12
CRISM Therapeutics Corporation to Report Q2, 2025 Results on Sep 15, 2025 CRISM Therapeutics Corporation announced that they will report Q2, 2025 results on Sep 15, 2025 Anuncio • Sep 01
CRISM Therapeutics Corporation Receives Regulatory and Ethical Approval for Registration-Grade Phase 2 Trial of Irinotecan-ChemoSeed in Glioblastoma CRISM Therapeutics Corporation confirmed that it has received both regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and favourable ethical opinion from a UK Research Ethics Committee (REC) to initiate its open label registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™? in patients with surgically resectable glioblastoma. This dual approval marks a significant operational milestone and clears the Company to commence the trial across selected UK clinical sites in first quarter of 2026, as planned. The approved study, titled "An Open-label Phase 2 Safety and Efficacy Trial of Irinotecan ChemoSeed Administered Directly into the Resection Margin in Patients with Surgically Resectable Glioblastoma", is designed to assess the safety, tolerability, and efficacy of irinotec an-ChemoSeed, CRISM's proprietary, biodegradable implant technology delivering sustained-release irinotecan directly into the tumour resection margin following surgical removal of the glioblastoma tumour. The trial has been designed in alignment with regulatory expectations for future marketing authorisation submissions. Key Highlights: Regulatory (MHRA) and Ethical (REC) approval received; Trial confirmed to initiate in first quarter of 2026 at leading UK neuro-oncology centres; Open-label format supports interim analysis, reporting of early results and potential for expedited regulatory approval; ChemoSeed platform targets local recurrence with sustained, localised chemotherapy; Registration-grade Phase 2 design supports pathway to marketing authorisation and commercialisation. CRISM is working with its CRO, Aixial Group, to activate the first site in the UK and start to enrol patients in first quarter of 2026. Further details of the trial are included in the Submission of Clinical Trial Authorisation application to the MHRA announcement on 01 July 2025. Anuncio • Aug 13
CRISM Therapeutics Announces GMP Manufacture of ChemoSeed for Phase 2 Clinical Trial in Glioblastoma CRISM Therapeutics announced the initiation of production of a clinical batch of ChemoSeed, its proprietary sustained-release implant containing irinotecan, under Good Manufacturing Practice (GMP). This clinical batch will be produced for the Company's upcoming open-label Phase 2 safety and efficacy trial evaluating ChemoSeed administered directly into the resection margin in patients with surgically resectable glioblastoma. US-based ProMed Pharma LLC, a Contract Development and Manufacturing Organisation ("CDMO"), will produce the clinical batch. The start of production marks a critical step toward first patient dosing, expected in First Quarter 2026, and underscores CRISM's commitment to addressing the significant unmet need in glioblastoma, a highly aggressive brain cancer with poor prognosis and limited effective treatment options. The Phase 2 study is designed to evaluate both safety and efficacy following direct administration of ChemoSeed into the tumour resection margin, with the goal of delivering a local high-dose of chemotherapy over a sustained period of time, while minimising systemic toxicity. This innovative approach builds on positive preclinical and early clinical data and has the potential to redefine the standard of care in post-surgical glioblastoma management. Anuncio • Aug 05
CRISM Therapeutics Corporation, Annual General Meeting, Aug 26, 2025 CRISM Therapeutics Corporation, Annual General Meeting, Aug 26, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Anuncio • Jul 04
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.054021 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.054021 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 450,176
Price\Range: £0.12 Anuncio • Mar 31
CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation Application CRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify. Anuncio • Mar 28
CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UK CRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed. Anuncio • Sep 09
CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024 CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024 Anuncio • May 15
Amur Minerals Corporation, Annual General Meeting, May 29, 2024 Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Anuncio • Nov 13
Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023 Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom Anuncio • Sep 25
Amur Minerals Corporation Announces Special Dividend Amur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment. Anuncio • Sep 07
Amur Minerals Announces Suspension of Trading on AIM Amur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate. Anuncio • Aug 10
Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources Plc Ascent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur. Anuncio • Jun 02
Ascent Resources Announces Intention to Bid for Amur Minerals The board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming. Anuncio • May 25
Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023 Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Tom Bowens was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Anuncio • Nov 10
Amur Minerals Corporation, Annual General Meeting, Dec 05, 2022 Amur Minerals Corporation, Annual General Meeting, Dec 05, 2022, at 10:00 Coordinated Universal Time. Location: Fieldfisher LLP, Riverbank House, 2 Swan Lane London, EC4R 3TT, UK London (United Kingdom) United Kingdom Board Change • Sep 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Tom Bowens was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Anuncio • Aug 06
Bering Metals LLC agreed to acquire Kun-Manie Project from Amur Minerals Corporation (AIM:AMC) for $35 million\. Bering Metals LLC agreed to acquire Kun-Manie Project from Amur Minerals Corporation (AIM:AMC) for $35 million on August 5, 2022. Anuncio • May 09
Amur Minerals Corporation, Annual General Meeting, May 25, 2022 Amur Minerals Corporation, Annual General Meeting, May 25, 2022. Agenda: Annual General Meeting. Anuncio • Jan 26
Amur Minerals Corp Confirms Talks to Sell Irosta Trading Amur Minerals Corporation confirmed that it is in discussions with a potential purchaser to sell its wholly owned subsidiary Irosta Trading Limited. Amur Minerals notes press speculation that a potentially interested party has valued company at an indicative price of up to £100 million. Amur Minerals Corp. to sell its wholly owned subsidiary, Irosta Trading Limited, for approximately indicated price. Anuncio • Jul 06
Hamilton Investments Pte. Ltd. acquired Carlo Holdings Limited from Amur Minerals Corporation (AIM:AMC) for $6.1 million. Hamilton Investments Pte. Ltd. acquired Carlo Holdings Limited from Amur Minerals Corporation (AIM:AMC) for $6.1 million on July 3, 2021. Carlo Holdings reported a net income of $0.22 million and total asset of $4.9 million for the year ended December 31, 2020. The Amur Minerals intends to use the sale proceeds to fund the continued development of the far eastern located Kun-Manie nickel copper sulphide project and general working capital. SP Angel Corporate Finance acted as broker in this transaction.
Hamilton Investments Pte. Ltd. completed the acquisition of Carlo Holdings Limited from Amur Minerals Corporation (AIM:AMC) on July 3, 2021. Anuncio • Jun 30
Amur Minerals Corporation Announces Kun-Manie Jorc Resource Update 1.3 Mt of Nickel, 0.37 Mt of Copper Amur Minerals Corporation announced RPM Global's ("RPM") 25 June 2021 update to the Mineral Resource Estimate ("MRE") for its 100% owned Kun-Manie project ("Kun-Manie"). The MRE update includes all existing drill and trench results. The resource is contained within three deposits identified as Maly Kurumkon /Flangovy ("MKF"), Vodorazdelny ("VOD") and Ikenskoe /Sobolevsky /Kubuk ("ISK"). Based on a 0.3% nickel equivalent cut-off grade ("COG"), the global JORC ore tonnage has increased by 19.2 million tonnes ("Mt") (12.4%) to 174.3 Mt, by 156,000 nickel tonnes (13.5%) to 1.31 Mt of nickel (averaging 0.75% nickel) and by 53,000 copper tonnes (16.6%) to 372,000 copper tonnes (averaging 0.21% copper). Of the global resource available for utilisation in the development of a JORC Mining Ore Reserve ("MOR"), only Measured and Indicated categories qualify for inclusion. The global Measured plus Indicated resource now consists of 148.3 million ore tonnes containing 1.11 Mt nickel (averaging 0.75% nickel) and 0.31 million tonnes copper (averaging 0.21% copper). An additional 29.4 Mt Inferred ore tonnes averaging 0.69% nickel (204,000 nickel tonnes) and 0.20% copper (58,000 copper tonnes). By-product metal content have been estimated for cobalt, platinum, palladium, gold and silver, but are not reported herein as the nonbinding offtake payable terms for the by-product metals is limited. RPM has stated that in-fill drilling of the existing Inferred resources could expand the Measured and Indicated resource, and the limits of the mineralisation have not been fully defined in the down dip directions and in other areas where limited drilling indicates the presence of mineralisation within the licence boundary limits. Anuncio • Feb 18
Amur Minerals Corporation Reports That the Terms and Conditions for the Kun-Manie Detailed Exploration and Mine Production Licence, Have Been Amended and Registered with Rosnedra, the State Licensing Agency Amur Minerals Corporation reported that the terms and conditions for the Company's Kun-Manie Detailed Exploration and Mine Production Licence, have been amended and registered with Rosnedra, the State Licensing Agency. The certified modification to the DEMP was received 4 February 2021 from Amurnedra and is dated effective November 30, 2020. The amendments are related to the delivery dates for two terms and conditions specific to the registered 36 square kilometre licence. During processing of the amendment to the DEMP, work on the Permanent Conditions TEO has progressed, identifying further optimisation opportunities and continues toward completion. To further evaluate the quality of the TEO results, the Company engaged an external consultant to independently verify Oreall's work. In addition, RPM Global has been engaged to update the 20 March 2018 JORC resource estimates to include the 32,526.5 meters of drilling completed in 2018. The 169 holes are distributed throughout the Maly Kurumkon /Flangovy, Vodorazdelny and the now largest and constinuous Ikenskoe /Sobolevsky /Kubuk deposits. The combination of RPM's and Oreall's enables the Company to evaluate and compare the Project potential based on both Russian and western funding opportunities for joint venture alternatives, various and combined off take agreements and /or merger and acquisition considerations. The Company submitted the application to amend the delivery date of the December 1, 2020 TEO which has now been successfully extended to December 1, 2021 for its delivery. Necessitated by delays induced by the Covid-19 pandemic where the impact of working remotely, the need to maintain social distancing and timely availability of key contract personnel, the Company submitted the application to amend the delivery date of the December 1, 2020 TEO. The amended delivery date for the TEO has been extended to December 1, 2021. In addition, the delivery date of the ensuing Mine Plan design has been extended. This work can only be implemented post-delivery of the TEO and its subsequent approval allowing for Russian reserve registration in accordance to the State Committee on Reserves regulatory requirements. The Mine Plan is now due June 1, 2023. During the DEMP modification process, ongoing work has continued toward completion of the TEO. As reported in a RNS dated November 25, 2020, the remainder of the work necessary for completion of the TEO included the compilation of capital and operating costs and the subsequent evaluation of economic potential of the Project per Russian Federation standards and requirements. Open pit designs generated by Oreall are also being independently evaluated. An independent evaluation by an external consultant will provide additional pit designs for a greater number of cutoff grades than the Oreall scope of work which is linked to Russian regulatory criteria which evaluates fewer designs at specific cutoff grades. Previous western study work on the MKF deposit by RPM confirmed a combination of open pit and underground operation would generate an enhanced revenue flow on this Project. Ongoing Company audits and reviews of the Oreall TEO results have identified the need to include Russian based open pit versus underground trade off studies allowing for the identification of a preferred life of mine production scenario for the deposits of MKF and ISK. VOD is an open pit only target as the depth of the mineralisation is at and near the surface. For MKF and ISK, results presently indicate a staged operation may be best for the development and life of mine production plans. This work is under evaluation. RPM is presently compiling an update to the JORC resource estimates for MKF, VOD and ISK. These results will provide the ability for the Company to directly compare the Russian and western resource /reserve generated results. RPM's and Oreall's work will also provide the Company with the ability to evaluate and compare the Project potential based on both Russian and western funding opportunities that may be considered from Russian versus western joint venture alternatives, various off take companies and /or merger and acquisition potential. Anuncio • Dec 23
Amur Minerals Corporation Announces Resignation of Paul Mckay as Chief Financial Officer, with Effect from December 31, 2020 Amur Minerals Corporation that Mr. Paul McKay, non-board Chief Financial Officer, will be leaving Amur on 31 December 2020. The Company has appointed Heytesbury Corporate LLP to provide company secretarial and accounting services. Mr. Paul McKay has been working with Heytesbury during a handover period. Anuncio • Nov 27
Amur Minerals Corporation Provides an Update on the Progress of the Compilation of Its TEO for Its Far East Russian Kun-Manie Nickel Copper Sulphide Project Amur Minerals Corporation provided an update on the progress of the compilation of its TEO for its far east Russian Kun-Manie nickel copper sulphide project. A TEO is a mandatory Russian feasibility study addressing the physical and operating project considerations paving the way for registration of the project's mineral reserve by the State Committee on Reserves. Reserve registration is a necessary milestone for a company to undertake detailed engineering, procurement and construction designs suited for compilation of a Bankable Feasibility Study, also referred to as a Definitive Feasibility Study. Per the terms and conditions of the mining licence, the TEO is due for submission to Russian authorities on 1 December 2020. Since March 30, the numerous companies involved in compilation of the TEO have been working remotely from their offices due to the COVID 19 pandemic. In addition, the recent surge in infections throughout Russia has impacted schedule. On a precautionary basis and in October the company applied for an extension of the delivery with Amurnedra who delivered the necessary documentation to Rosnedra in Moscow. Currently, work continues to advance the final sections of the report, being the completion of the economic and financial valuation. This includes finalization of the capital and operating expenditures related to the project and development of a cash flow model with estimated revenues, capital and operating expenditures, taxes, depreciation and sustaining capital expenditures. Some work remains on the environmental response action plan. Once complete, the final draft of the report will be submitted to the Company for review and finalization. However, due to remote nature of the compilation of this report, the extensive amount of required hard copy documentation is progressing, though not as rapid as originally scheduled and is now expected to be completed in first quarter 2021. Anuncio • Nov 13
Amur Minerals Corporation, Annual General Meeting, Dec 10, 2020 Amur Minerals Corporation, Annual General Meeting, Dec 10, 2020, at 10:00 Coordinated Universal Time. Location: the offices of Brunton Publications Limited 1 London Road, Bishopdown Sailsbury United Kingdom Anuncio • Aug 29
Amur Minerals Corporation has completed a Follow-on Equity Offering in the amount of £6.1 million. Amur Minerals Corporation has completed a Follow-on Equity Offering in the amount of £6.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 348,571,421
Price\Range: £0.0175
Transaction Features: Subsequent Direct Listing